HomeAI · summaries
Storia in 4 fonti
ASCO: AstraZeneca's Imfinzi, Imjudo duo shines in earlier-stage liver cancer
AstraZeneca is polishing the case for its Imfinzi (durvalumab) and Imjudo (tremelimumab) combo in liver cancer with a new phase 3 readout from its Emerald trial program assessing the immunotherapy | The company's Emerald-3 study showed a 30% reduction in the risk of disease progression or death among embolization-eligible liver cancer patients who used an Imfinzi and Imjudo regimen.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
AstraZeneca seeks path for failed antibody; Imfinzi, Tremfya get label expansions
AstraZeneca seeks a narrower path for failed antibody; Imfinzi and Tremfya label expansions
- ·
fiercepharma.com
ASCO: With bispecifics on its heels, Incyte positions Monjuvi combo for first-line DLBCL
Seeking a share of the first-line diffuse large B-cell lymphoma (DLBCL) market, Incyte believes Monjuvi’s positive phase 3 results across patient subgroups will give it an edge…
